Wordt geladen...
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in elderly, transplant-ineligible patients with newly diagnosed multiple myeloma. Primary phase I objectives were to determine the safety and recommen...
Bewaard in:
| Gepubliceerd in: | Haematologica |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Ferrata Storti Foundation
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6119151/ https://ncbi.nlm.nih.gov/pubmed/29954932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.185991 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|